• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. and Ticker Symbol Change to "SCNX"

    9/24/24 8:01:00 AM ET
    $MEDS
    $SCNX
    Other Pharmaceuticals
    Health Care
    Other Pharmaceuticals
    Health Care
    Get the next $MEDS alert in real time by email

    TRxADE Health, Inc. today announced that it changed its name and ticker symbol to "Scienture Holdings, Inc." and "SCNX", respectively, and that the business will continue as a Nasdaq-listed company.

    TAMPA, FL, Sept. 24, 2024 (GLOBE NEWSWIRE) -- TRxADE Health, Inc. (the "Company") (NASDAQ:MEDS) and Scienture, LLC ("Scienture"), a wholly owned subsidiary of the Company, today announced that the Company has changed its name to "Scienture Holdings, Inc." Effective as of September 23, 2024, the Company's stock is now trading on the Nasdaq Stock Market LLC under the new ticker symbol "SCNX".

    Scienture Holdings, Inc., through its wholly owned subsidiaries, Scienture and Integra Pharma Solutions, LLC ("IPS"), is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Our products are in development across therapeutic areas and indications, and cater to different market segments and channels.

    Our executive team and board of directors, listed below, consist of accomplished industry veterans, bringing many years of experience and leadership.

    Suren Ajjarapu – CEO of the Company and Chairman of the Board of Directors (the "Board")

    Prashant Patel – President, Interim CFO and COO of the Company and Member of the Board

    Shankar Hariharan, Ph.D. – CEO of Scienture and Member of the Board Narasimhan Mani, Ph.D., MBA – President of Scienture and Member of the Board

    Donald Fell – Member of the Board

    Mayur Doshi – Member of the Board

    Subbarao Jayanthi – Member of the Board

    About Scienture, LLC

    Scienture, LLC is a NY based pharmaceutical company. We are a highly experienced team of industry professionals who are passionate about developing unique specialty product concepts and solutions that bring enhanced value to patients and healthcare systems. Our assets in development are across therapeutics areas, indications and cater to different market segments. Scienture is a fully fitted company with strategic capabilities across R&D, Manufacturing, Sales and Marketing and Commercial Operations. For more information, visit Scienture's website at www.scienture.com/scienture-llc/.

    About Integra Pharma Solutions, LLC

    Integra Pharma Solutions, LLC is the pharmaceutical supplier of choice for healthcare organizations of all sizes. Our expertise in the distribution of products extends all healthcare markets including Government Organizations, Hospitals, Clinics, and Independent Pharmacies nationwide. IPS holds pharmaceuticals distributor licenses in 39 states and supplies pharmaceuticals, diabetic supplies, veterinary, PPE products and more. It offers efficient solutions to manufacturers and distributors to further lower cost and increase pharmaceutical access. For more information, visit IPS' website at www.rxintegra.com.

    Cautionary Statements Regarding Forward-Looking Statements

    This press release contains certain statements that may be deemed to be "forward-looking statements" within the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "ongoing," "plan," "potential," "predict," "project," "should," or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability to maintain the listing of our common stock on the Nasdaq Capital Market; claims relating to alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings that may be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks detailed in our most recent Annual Report on Form 10-K and subsequent reports filed with the SEC.

    Forward-looking statements speak only as of the date they are made. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law.

    Contacts:

    Scienture Holdings, Inc.

    Scienture Holdings, Inc.

    6308 Benjamin Rd, Suite 708

    Tampa, Florida 33634

    Phone: (866) 468-6535

    Email: [email protected]

    Scienture, LLC

    Scienture, LLC

    20 Austin Boulevard

    Commack, New York 11725

    Phone: (631) 670-6039

    Email: [email protected]



    Primary Logo

    Get the next $MEDS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MEDS
    $SCNX

    CompanyDatePrice TargetRatingAnalyst
    TRxADE HEALTH Inc.
    $MEDS
    12/9/2021$4.50Buy
    EF Hutton
    More analyst ratings

    $MEDS
    $SCNX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025.

      TAMPA, FL, April 22, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce the initiation of supply chain activities by its wholly owned subsidiary Scienture, LLC to manufacture launch quantities of ArbliTM (losartan potassium) Oral Suspension, 10 mg/mL for the intended commercial launch of the product in July 2025. Scirenture, LLC's contract manufacturing partner, Saptalis Pharmaceuticals, LLC

      4/22/25 8:04:59 AM ET
      $SCNX
      Other Pharmaceuticals
      Health Care
    • SCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC.

      TAMPA, FL, April 08, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) (the "Company"), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, announced the divestiture of its legacy Healthcare IT and Wholesale Operations subsidiaries Integra Pharma Solutions (IPS), Bonum Health, Inc., and Softell, Inc. to Tollo Health, Inc. for a total consideration of $5 million. The divestitures are part of a broader strategic realignment at the Company designed to sharpen operatio

      4/8/25 8:05:00 AM ET
      $SCNX
      Other Pharmaceuticals
      Health Care
    • Scienture Holdings, Inc. Issues Annual Letter to Shareholders

      TAMPA, FL, April 03, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to provide this annual update from its Chief Executive Officer, Surendra Ajjarapu, to its stockholders. This time last year, Scienture Holdings, Inc. (f.k.a. TRxADE Health, Inc.). was focused on health services IT assets and operations aimed at digitalizing the retail pharmacy experience. The primary operations were conducted through

      4/3/25 8:26:00 AM ET
      $SCNX
      Other Pharmaceuticals
      Health Care

    $MEDS
    $SCNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • EF Hutton initiated coverage on Trxade Health with a new price target

      EF Hutton initiated coverage of Trxade Health with a rating of Buy and set a new price target of $4.50

      12/9/21 9:10:50 AM ET
      $MEDS
      Other Pharmaceuticals
      Health Care
    • Maxim Group initiated coverage on Trxade Group

      Maxim Group initiated coverage of Trxade Group with a rating of Buy

      2/26/21 8:08:35 AM ET
      $MEDS
      Other Pharmaceuticals
      Health Care

    $MEDS
    $SCNX
    Leadership Updates

    Live Leadership Updates

    See more
    • Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO

      SARASOTA, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company advancing innovative treatments for brain-related health conditions, today provided an update on its strategic progress since its last capital raise in September 2024. The Company also announced the appointment of Janet Huffman as its new interim Chief Executive Officer. Strategic Progress Since Capital Raise Following the Company's $4 million capital raise in September 2024, the Company has made significant advancements, including: Formulation and Device Enhancements: The Company has improved the formulation and intranasal delivery device for ONP-002 and in connection therewith

      1/21/25 8:15:00 AM ET
      $MEDS
      $OGEN
      Other Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • TRxADE Health, Inc. Announces New Addition and Changes to Scienture, LLC's Executive Leadership Team

      TAMPA, FL and COMMACK, NY, Aug. 05, 2024 (GLOBE NEWSWIRE) -- TRxADE Health, Inc. ("TRxADE") (NASDAQ:MEDS) and Scienture, LLC ("Scienture"), a wholly owned subsidiary of TRxADE, today announced the appointment of Narasimhan Mani, Ph.D., MBA as Scienture's President. Shankar Hariharan, Ph.D., the current President and CEO, will be CEO of Scienture. Rahul Surana, Ph.D., MBA has been promoted to Executive VP and COO of Scienture. Dr. Narasimhan Mani is an experienced healthcare professional and a proven leader with over 25 years of experience in both the scientific and business areas of the pharmaceutical industry. He currently is a part of the Executives-in-Residence program at New Rhein Hea

      8/5/24 8:01:00 AM ET
      $MEDS
      Other Pharmaceuticals
      Health Care
    • Newly merged Entity Superlatus, Inc with Trxade Health, Inc. Appoints Leading CPG Management Team

      Forbes Fisher Appointed as Chief Operating Officer.Dr. Eugenio Bortone Appointed as Chief Innovation & Food Technology Officer. TAMPA, FL, Aug. 03, 2023 (GLOBE NEWSWIRE) -- TRxADE HEALTH, Inc (NASDAQ:MEDS), parent company of pharmaceutical B2B exchange platform, which recently merged with Superlatus, Inc today announced the appointments of Forbes Fisher as Chief Operating Officer and Dr. Eugenio (Gino) Bortone as Chief Innovation & Food Technology Officer. Forbes brings over 25 years of Food Services industry experience and will lead product innovation and information technology, and drive sales and supply chain optimization to support growth and profitability initiatives. Dr. Eugenio

      8/3/23 9:05:00 AM ET
      $MEDS
      Other Pharmaceuticals
      Health Care

    $MEDS
    $SCNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $MEDS
    $SCNX
    SEC Filings

    See more
    • SEC Form SC 13G/A filed by TRxADE HEALTH Inc. (Amendment)

      SC 13G/A - TRxADE HEALTH, INC (0001382574) (Subject)

      2/14/24 2:50:57 PM ET
      $MEDS
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13G filed by TRxADE HEALTH Inc.

      SC 13G - TRxADE HEALTH, INC (0001382574) (Subject)

      2/14/23 1:05:54 PM ET
      $MEDS
      Other Pharmaceuticals
      Health Care
    • SEC Form SC 13D/A filed by TRxADE HEALTH Inc. (Amendment)

      SC 13D/A - TRxADE HEALTH, INC (0001382574) (Subject)

      10/19/22 4:30:15 PM ET
      $MEDS
      Other Pharmaceuticals
      Health Care
    • SEC Form 424B3 filed by Scienture Holdings Inc.

      424B3 - Scienture Holdings, Inc. (0001382574) (Filer)

      4/24/25 4:05:28 PM ET
      $SCNX
      Other Pharmaceuticals
      Health Care
    • SEC Form EFFECT filed by Scienture Holdings Inc.

      EFFECT - Scienture Holdings, Inc. (0001382574) (Filer)

      4/14/25 12:15:17 AM ET
      $SCNX
      Other Pharmaceuticals
      Health Care
    • SEC Form 424B3 filed by Scienture Holdings Inc.

      424B3 - Scienture Holdings, Inc. (0001382574) (Filer)

      4/11/25 4:50:55 PM ET
      $SCNX
      Other Pharmaceuticals
      Health Care

    $MEDS
    $SCNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Shankar Hariharan claimed ownership of 97,087 shares (SEC Form 3)

      3 - TRxADE HEALTH, INC (0001382574) (Issuer)

      8/5/24 9:23:01 PM ET
      $MEDS
      Other Pharmaceuticals
      Health Care
    • New insider Narasimhan Mani claimed ownership of 57,977 shares (SEC Form 3)

      3 - TRxADE HEALTH, INC (0001382574) (Issuer)

      8/5/24 9:23:00 PM ET
      $MEDS
      Other Pharmaceuticals
      Health Care
    • Ajjarapu Surendra K was granted 10,000 shares (SEC Form 4) (Amendment)

      4/A - TRxADE HEALTH, INC (0001382574) (Issuer)

      5/28/24 5:01:21 PM ET
      $MEDS
      Other Pharmaceuticals
      Health Care

    $MEDS
    $SCNX
    Financials

    Live finance-specific insights

    See more
    • TRxADE Health, Inc. Announces Special Cash Dividend

      TAMPA, FL, July 09, 2024 (GLOBE NEWSWIRE) -- TRxADE HEALTH, INC. (NASDAQ:MEDS) (the "Company"), announced that the Company's board of directors has declared a special cash dividend of $1.50 per share of common stock. The special dividend is being paid using a portion of the proceeds received in May 2024 in connection with the prior sale of the Company's web-based market platform assets. The special cash dividend is payable to stockholders of record as of July 19, 2024, with the dividend being paid on or about July 24, 2024. Forward-Looking Statements This press release contains certain statements that may be deemed to be "forward-looking statements" within the federal securities laws, in

      7/9/24 8:05:00 AM ET
      $MEDS
      Other Pharmaceuticals
      Health Care
    • TRxADE Health, Inc. Announces Special Cash Dividend

      TAMPA, FL, March 06, 2024 (GLOBE NEWSWIRE) -- TRxADE HEALTH Inc. (NASDAQ:MEDS) (the "Company"), announced that the Company's board of directors has declared a special cash dividend of $8.00 per share of common stock. The special dividend is being paid using a portion of the proceeds from the closing of the recently announced sale of the Company's web-based market platform assets. The special cash dividend is payable to stockholders of record as of March 18, 2024, with the dividend being paid on or about March 22, 2024. Forward-Looking Statements This press release contains certain statements that may be deemed to be "forward-looking statements" within the federal securities laws, includi

      3/6/24 8:05:00 AM ET
      $MEDS
      Other Pharmaceuticals
      Health Care
    • Superlatus, Newly Merged with TRxADE HEALTH, Acquires the assets of Spero Foods, a plant-based tech company Disrupting the Dairy and Egg Industry.

      Spero is another addition to the growing Superlatus CPG portfolio under their Urgent Company umbrella of brands.Spero® is a plant-based tech company specializing in alternative dairy and egg replacements, on a mission to outcompete traditional dairy and egg products in scale, price, taste, and nutrition by utilizing internationally patent-pending technologies that transforms low-cost, sustainable, and scalable ingredients into plant-based alternatives. Spero's mission is to scale mainstream dairy alternatives and have them be delicious, affordable, and available to everyone, everywhere. TAMPA, FL, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Superlatus, Inc. ("Superlatus"), wholly owned subsidary of

      10/4/23 8:05:00 AM ET
      $MEDS
      Other Pharmaceuticals
      Health Care